Transgene (FRA:TGNA) Inventories, Work In Process: €0.00 Mil (As of Dec. 2025)


FRA:TGNA Transgene SA FRA:TGNA
43 GF Score
Price €0.71
GF Value €0.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene Inventories, Work In Process?

Transgene FRA:TGNA +0.14% 43 Inventories, Work In Process is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:TGNA with a GF Score™ of 43/100 and a GF Value™ of €0.52 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Transgene's work in process for the quarter that ended in Dec. 2025 was €0.00 Mil.

Transgene Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Transgene's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Inventories, Work In Process Chart

Transgene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Transgene Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:TGNA
43GF Score
Transgene SA FRA:TGNA
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €0.00 Mil mean?
Transgene (FRA:TGNA) has a Inventories, Work In Process of €0.00 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Transgene and its competitors.
Is Transgene's Inventories, Work In Process too high?
Transgene's current Inventories, Work In Process is €0.00 Mil. Overall, Transgene has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transgene's Inventories, Work In Process compare to VRTX and REGN?
Transgene's Inventories, Work In Process of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Transgene and its competitors. Transgene's current Inventories, Work In Process is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene stock overvalued right now?
Based on GuruFocus' analysis, Transgene (FRA:TGNA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.52, compared to a current price of €0.71 — trading 35.6% above its estimated fair value. The current Inventories, Work In Process is €0.00 Mil. Transgene's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Transgene (FRA:TGNA), the current Inventories, Work In Process is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene (FRA:TGNA) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.71 is trading 35.6% above its estimated GF Value™ of €0.52. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for FRA:TGNA:

  • Inventories, Work In Process: €0.00 Mil
  • GF Value™: €0.52 vs. price of €0.71 (35.6% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the FRA:TGNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Other Exchanges TRGNF:USA0OCQ:UKTNG:France
Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
43GF Score

Get the complete analysis for FRA:TGNA

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.71
Price
€0.52
GF Value